Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

Latest from Mays Cancer Center at UT Health San Antonio

Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis

December 07, 2020

Video

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 01, 2020

Video

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. Mesa on Management Strategies for MPNs

October 23, 2020

Video

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16, 2020

Video

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15, 2020

Video

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Dr. Mesa on Emerging Therapies in Myelofibrosis

September 23, 2020

Video

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis

September 11, 2020

Video

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis.

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

September 09, 2020

Video

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Dr. Mesa on Accrual Considerations in MPN Clinical Trials

August 17, 2020

Video

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials.

Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNs

August 13, 2020

Video

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

August 10, 2020

Video

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Dr. Mesa on Mitigating Racial Disparities in MPN Clinical Trials

August 05, 2020

Video

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

August 03, 2020

Video

Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.

Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis

April 21, 2020

Video

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Dr. Mesa on Treatment Advancements Made in MPNs

April 16, 2020

Video

Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.

Mesa Provides Perspective on Diagnosis and Treatment in Essential Thrombocythemia

April 15, 2020

Article

Ruben A. Mesa, MD, discusses the current state of ET treatment, the challenges of diagnosing the disease, and available educational resources for healthcare providers and patients.